FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
15/04/2024
Voltar para busca
Dado oficial do USPTO
RADELUMIN
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
26
Atualização mais recente
15/04/2024
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
31/03/2022
Data de registro
12/12/2023
Data de expiração
-
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
12/12/2023
Última transação
12/12/2023
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
27
Localização do titular
DE
Examinador
MAHMOUDI, MARIAM AZIZ
Unidade examinadora
M60
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
ABX advanced biochemical compounds - Biomedizinische Forschungsreagenzien GmbH
Representantes
Philip C. Schroeder Buchalter
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Medical and veterinary preparations for the diagnosis of diseases of the prostate; medical and veterinary preparations for the treatment of diseases of the prostate; medical and veterinary preparations for the diagnosis of cancer; medical and veterinary preparations for the treatment of cancer; dietetic foods and beverages adapted for medical or veterinary purposes; chemical preparations for medical or pharmaceutical purposes for the diagnosis of diseases of the prostate; chemical preparations for medical or pharmaceutical purposes for the treatment of diseases of the prostate; chemical preparations for medical or pharmaceutical purposes for the diagnosis of cancer; chemical preparations for medical or pharmaceutical purposes for the treatment of cancer; biological preparations for medical or pharmaceutical purposes for the diagnosis of diseases of the prostate; biological preparations for medical or pharmaceutical purposes for the treatment of diseases of the prostate; biological preparations for medical or pharmaceutical purposes for the diagnosis of cancer; biological preparations for medical or pharmaceutical purposes for the treatment of cancer; preparations for use in medical diagnostic processesdiagnostic preparations for medical purposes; preparations for use in medical diagnostic processesdiagnostic preparations for medical purposes relating to the diagnosis of diseases of the prostate; preparations for use in medical diagnostic processesdiagnostic preparations for medical purposes relating to the diagnosis of cancer
Publicações
Histórico de despachos e eventos da marca no USPTO.
26 publicações encontradas
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
15/03/2024
XXCR
GENERIC MADRID TRANSACTION CREATED
15/03/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
12/03/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/12/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
12/12/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
26/09/2023
PUBO
PUBLISHED FOR OPPOSITION
26/09/2023
GPNX
NOTIFICATION PROCESSED BY IB
25/09/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
06/09/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
06/09/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/09/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
22/08/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
22/08/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
21/08/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
21/08/2023
RFNP
REFUSAL PROCESSED BY IB
13/04/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
17/03/2023
RFRR
REFUSAL PROCESSED BY MPU
16/03/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
25/01/2023
CNRT
NON-FINAL ACTION WRITTEN
24/01/2023
DOCK
ASSIGNED TO EXAMINER
18/01/2023
MAFR
APPLICATION FILING RECEIPT MAILED
06/09/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
31/08/2022
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
30/08/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
25/08/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace RADELUMIN ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.